Pulmonary vascular disease & thromboembolism
Mono and Combination Therapies in Pulmonary Arterial Hypertension Patients with Comorbidities: A COMPERA Analysis
Authors' conclusion
This analysis suggests that PAH patients with comorbidities may benefit more pronounced from combination therapy regarding WHO-FC, BNP/NT-pro-BNP and risk status without a significant difference in survival. Good tolerability is indicated. However, given the relatively younger patient matched subgroup, these findings may not necessarily apply to older patients with a wider range of comorbidities.
Study context
- Population
- Adult patients with incident pre-capillary pulmonary arterial hypertension (PAH) and cardiovascular comorbiditiesmatched pairs, enrolled patient population n = 1871
- Participants
- 216 pairs patients
- Exposure
- Patients treated with monotherapy versus combination therapy
- Outcome
- WHO-FC, BNP/NT-proBNP and risk status
Methodological detailsregistry data (COMPERA database, European registry for PH)
- Registry data (COMPERA database, European registry for PH)
Main finding
As reported in the abstract
- Initial combination therapy group showed more pronounced improvements in WHO-FC, BNP/NT-proBNP and risk status than initial monotherapy
- Matched-pair analysis
Observational data: associations, not effects.
Further findings
| Outcome | Mono | Combination |
|---|---|---|
| Mean age, matched pairs vs enrolled population | ||
| Matched pairs | 62.9 ± 13.5 | 62.0 ± 13.6 |
| Enrolled population | 70.6 ± 11.4 | 60.5 ± 14.9 |
6MWD, PAH-related hospitalisations, survival and drug discontinuation
- No significant differences
- Matched-pair analysis
Original publication
Mono and Combination Therapies in Pulmonary Arterial Hypertension Patients with Comorbidities: A COMPERA Analysis. ESC Heart Fail. Published 4 March 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →